Skip to content
PeptideTech
sign in
live116 compounds · 15 vendors listed · 7 graded · audit of 4 Nov 2026 · prices checked 6 Nov 2026independent · grades can’t be bought

Home / Research library / Nefiracetam Powder

Nootropics

Nefiracetam Powder: molecular data, studies & sources

Nefiracetam Powder is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF)
C14H18N2O2
Molecular weight (MW)
246.30 g/mol
PubChem compound ID
71157
Record title
Nefiracetam

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 71157 · retrieved 2026-09-21

2D molecular structure for Nefiracetam Powder, PubChem CID 71157
2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.
Chemical identifiers and source data
IUPAC name
N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide
InChIKey
NGHTXZCKLWZPGK-UHFFFAOYSA-N
SMILES
CC1=C(C(=CC=C1)C)NC(=O)CN2CCCC2=O
Machine-readable PubChem source

Identifiers

PubChem CID
71157
CAS Registry Number
77191-36-7via ChemIDplus, EPA DSSTox, FDA GSRS
FDA UNII
1JK12GX30N
ChEMBL ID
CHEMBL260829
InChIKey
NGHTXZCKLWZPGK-UHFFFAOYSA-N
Wikidata
Q6039388

Other names and development codes: NSC-759830

CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.

Calculated molecular descriptors
Monoisotopic (exact) mass246.1368 Da
Heavy atoms18
Hydrogen-bond donors1
Hydrogen-bond acceptors2
Rotatable bonds3
Topological polar surface area49.4 Ų
Calculated logP (Crippen)1.86
Rings2
Stereocenters0
Formal charge0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

US regulatory status & drug development

Drug development record (ChEMBL)

Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.

ChEMBL ID
CHEMBL260829
Modality
Small molecule
Highest clinical stage
Phase 2
Record name
NEFIRACETAM
Synonyms, codes and trade names
Synonyms and development codes
Nefiracetam · NSC-759830

Identity check: Identical standard InChIKey to the PubChem record. Source: ChEMBL CHEMBL260829 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-07

Registered clinical trials

Studies registered on ClinicalTrials.gov that list Nefiracetam as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

1 registered study matched.

By highest phase
Phase 2 · 1
By registry status
Completed · 1
StudyPhase · statusConditionsSponsor · size
Nefiracetam in the Treatment of Alzheimer's DiseaseNCT00001933 · start 1999-07Phase 2CompletedAlzheimer's DiseaseNational Institute of Neurological Disorders and Stroke (NINDS)50 participants

Registry check 2026-10-09 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received Nefiracetam, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

  1. Human study · PubMed trial index Compound given to participants

    Double-blind randomized treatment of poststroke depression using nefiracetam.

    Robinson RG, Jorge RE, Clarence-Smith K et al. · The Journal of neuropsychiatry and clinical neurosciences · 2008

    PMID 18451188 · DOI: 10.1176/jnp.2008.20.2.178

  2. Human study · PubMed trial index Compound given to participants

    A Randomized, Placebo-Controlled, Double-Blind Efficacy Study of Nefiracetam to Treat Poststroke Apathy.

    Starkstein SE, Brockman S, Hatch KK et al. · Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2016

    PMID 26915605 · DOI: 10.1016/j.jstrokecerebrovasdis.2016.01.032

  3. Human study · PubMed trial index Compound given to participants

    Double-blind treatment of apathy in patients with poststroke depression using nefiracetam.

    Robinson RG, Jorge RE, Clarence-Smith K et al. · The Journal of neuropsychiatry and clinical neurosciences · 2009

    PMID 19622685 · DOI: 10.1176/jnp.2009.21.2.144

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

  1. Review · secondary evidence

    Nefiracetam. DM 9384, DZL 221, Translon.

    · Drugs in R&D · 2002

    PMID 12099172 · DOI: 10.2165/00126839-200203030-00017

  2. Preclinical / laboratory research

    Effects of the nootropic drug nefiracetam on the GABAA receptor-channel complex in dorsal root ganglion neurons.

    Huang CS, Ma JY, Marszalec W et al. · Neuropharmacology · 1996

    PMID 9014140 · DOI: 10.1016/s0028-3908(96)00074-3

  3. Preclinical / laboratory research

    Nefiracetam improves Morris water maze performance following traumatic brain injury in rats.

    DeFord SM, Wilson MS, Gibson CJ et al. · Pharmacology, biochemistry, and behavior · 2001

    PMID 11509223 · DOI: 10.1016/s0091-3057(01)00559-7

  4. Review · secondary evidence

    [Facilitatory actions of the cognitive enhancer nefiracetam on neuronal Ca2+ channels and nicotinic ACh receptors: their intracellular signal transduction pathways].

    Yoshii M, Nishizaki T, Watabe S et al. · Nihon yakurigaku zasshi. Folia pharmacologica Japonica · 1998

    PMID 10190131 · DOI: 10.1254/fpj.112.supplement_41

Nefiracetam Powder supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

Nefiracetam Powder for sale: compare prices, sizes and forms from every tracked supplier →

SupplierRecorded packagesExample source listing
Amino USAUSD10000mg Powder1 recorded offers10000mg Powder · $40.00Checked Nov 6, 2026Supplier listing, Nefiracetam Powder 10000mg Powder, Amino USA, opens in a new tab

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

Related research profiles

Nootropics

Agomelatine Powder

C15H17NO2

243.30 g/mol · PubChem CID 82148

8 selected publications · 5 human intervention studies · 19 registered trials

Small molecule · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)

Structure, studies & sources →